Bergen, Norway, 27 November 2017 - BerGenBio ASA (OSE: BGBIO), a clinical-stage
biopharmaceutical company developing novel, selective Axl kinase inhibitors for
multiple cancer indications, provides an update on BGBC004, an on-going, company
sponsored US study evaluating BGB324 in conjunction with TARCEVA® (erlotinib) in
patients with non-small cell lung cancer, in response to recent media coverage.
BerGenBio gained the required approvals from the US Food & Drug Administration
(FDA) and from the ethics committees at the participating US hospitals prior to
starting this study with BGB324. BerGenBio can confirm that it is in discussions
with the Regional Ethics Committee (REK) in Bergen and the Norwegian Board of
Health to gain retrospective approval to conduct the BGBC004 study in the US.
- Ends -
Contact
Richard Godfrey
CEO, BerGenBio ASA
+47 917 86 304
Tom Henrik Sundby
Finance Director, BerGenBio ASA
tom.sundby@bergenbio.com
+47 477 54 415
Media Relations
David Dible, Mark Swallow, Marine Perrier
Citigate Dewe Rogerson
bergenbio@citigatedewerogerson.com
+44 207 638 9571